What is Asceneuron?
Founded in 2012, Asceneuron specializes in the discovery and development of innovative small molecules aimed at halting neurodegeneration. The company operates at the intersection of advanced molecular biology and clinical pharmacology, focusing on high-unmet medical needs. By identifying and modulating key molecular pathways, Asceneuron seeks to provide disease-modifying treatments for conditions that have historically proven resistant to conventional therapeutic approaches. Its market position is defined by a rigorous scientific methodology and a strategic focus on orphan diseases, which allows for targeted clinical trials and a more streamlined path toward regulatory approval in both European and North American markets.
How much funding has Asceneuron raised?
Asceneuron has raised a total of $130.6M across 2 funding rounds:
Series A
$30.6M
Series C
$100M
Series A (2015): $30.6M with participation from Sofinnova Partners, Kurma Partners, SR One, and MS Ventures
Series C (2024): $100M led by SR One, OrbiMed, and Novo Holdings
Key Investors in Asceneuron
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics, leveraging its roots as a corporate venture arm.
OrbiMed
OrbiMed Advisors LLC is a specialized healthcare investment firm managing capital across biopharmaceuticals and medical devices, known for its multi-stage strategy and hands-on operational support.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term value creation in the life sciences sector.
What's next for Asceneuron?
With the successful closure of this major strategic investment, Asceneuron is well-positioned to advance its lead candidates through critical clinical milestones. The company's strategic roadmap likely involves expanding its internal research capabilities and strengthening its intellectual property portfolio to maintain a competitive edge in the neuro-therapeutics sector. Furthermore, the involvement of top-tier life sciences investors suggests a focus on operational excellence and potential future partnerships or licensing agreements that could amplify the reach of its therapeutic platform. As the firm scales, the primary objective remains the translation of its innovative scientific discoveries into tangible, life-altering medicines for patients suffering from debilitating neurodegenerative disorders.
See full Asceneuron company page
